Cargando…

Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes

BACKGROUND: Atypical antipsychotic medications are widely prescribed for the adjunctive treatment of depression, yet their total risk–benefit profile is not well understood. We thus conducted a systematic review of the efficacy and safety profiles of atypical antipsychotic medications used for the a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spielmans, Glen I., Berman, Margit I., Linardatos, Eftihia, Rosenlicht, Nicholas Z., Perry, Angela, Tsai, Alexander C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595214/ https://www.ncbi.nlm.nih.gov/pubmed/23554581 http://dx.doi.org/10.1371/journal.pmed.1001403

Ejemplares similares

Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder
por: Yan, Tingjian, et al.
Publicado: (2020)

Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature
por: Tsai, Alexander C., et al.
Publicado: (2011)

Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy
por: Nadkarni, Anagha, et al.
Publicado: (2013)

Atypical Antipsychotics and Other Therapeutic Options for Treatment of Resistant Major Depressive Disorder
por: Seo, Rubo J., et al.
Publicado: (2010)

Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder
por: Wen, X.J., et al.
Publicado: (2014)

New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression
por: Orzelska-Górka, Jolanta, et al.
Publicado: (2022)

Atypical antipsychotics as add-on treatment in late-life depression
por: Cakir, Sibel, et al.
Publicado: (2016)

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
por: Vieta, Eduard, et al.
Publicado: (2019)

Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: A systematic review and network meta-analysis
por: Wang, Jia, et al.
Publicado: (2023)

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori L., et al.
Publicado: (2016)

Call to Caution with the Use of Atypical Antipsychotics for Treatment of Depression in Older Adults
por: Amodeo, Katherine, et al.
Publicado: (2016)

Atypical antipsychotics, dystonia, and psychotic depression: old solutions for new problems
por: Gazzellone, Matthew J., et al.
Publicado: (2022)

Real-World Determinants of Adjunctive Antipsychotic Prescribing for Patients with Major Depressive Disorder and Inadequate Response to Antidepressants: A Case Review Study
por: McIntyre, Roger S., et al.
Publicado: (2015)

Anti-inflammatory effects of antidepressant and atypical antipsychotic medication for the treatment of major depression and comorbid arthritis: a case report
por: Baune, Bernhard T, et al.
Publicado: (2010)

Comment on: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”
por: Periclou, Antonia, et al.
Publicado: (2019)

Pooled Analysis Confirms Flibanserin's Unimpressive Efficacy, Raises Measurement Questions: A Commentary on Simon et al
por: Spielmans, Glen I.
Publicado: (2022)

Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2016)

Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis
por: Zhou, Xinyu, et al.
Publicado: (2015)

Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy
por: Nelson, J. Craig, et al.
Publicado: (2014)

PS78. Naturalistic, retrospective comparison between antidepressant therapy and atypical antipsychotic augmentation therapy for patients with major depressive disorder
por: Cho, Se Hoon, et al.
Publicado: (2016)

Use of Atypical Antipsychotics in Long-Term Care Residents with Parkinson’s Disease and Comorbid Depression
por: Chekani, Farid, et al.
Publicado: (2020)

Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis
por: Kadakia, Aditi, et al.
Publicado: (2021)

Cardiotoxicity of current antipsychotics: Newer antipsychotics or adjunct therapy?
por: Liu, Zheng, et al.
Publicado: (2022)

Measuring Response to Adjunctive Therapy Among Individuals with Major Depressive Disorder
por: Forma, Felicia, et al.
Publicado: (2022)

Safety and tolerability of edivoxetine as adjunctive treatment to selective serotonin reuptake inhibitor antidepressants for patients with major depressive disorder
por: Martinez, James M, et al.
Publicado: (2015)

Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open‐label, long‐term safety and tolerability study
por: Lepola, Ulla, et al.
Publicado: (2018)

Black Box Warning Did Not Cause Increased Suicides
por: Spielmans, Glen I., et al.
Publicado: (2021)

PS151. Adjunctive brexpiprazole (OPC-34712) in patients with major depressive disorder and anxiety symptoms: an exploratory study
por: Davis, Lori, et al.
Publicado: (2016)

Atypical Antipsychotics in the Treatment of Depressive and Psychotic Symptoms in Patients with Chronic Schizophrenia: A Naturalistic Study
por: Innamorati, Marco, et al.
Publicado: (2013)

The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression
por: Morais, M, et al.
Publicado: (2017)

Use of antipsychotics in the treatment of major depressive disorder in an outpatient mental health center
por: Garnier, Carolina, et al.
Publicado: (2010)

Efficacy of physical activity in the adjunctive treatment of major depressive disorders: preliminary results
por: Pilu, Alessandra, et al.
Publicado: (2007)

Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis
por: Kishimoto, Taishiro, et al.
Publicado: (2023)

Asenapine: an atypical antipsychotic with atypical formulations
por: Musselman, Meghan, et al.
Publicado: (2021)

Atypical antipsychotics, more than just an antipsychotic
por: Tendilla-Beltrán, Hiram, et al.
Publicado: (2020)

Adjunctive Bright Light Therapy for Non-Seasonal Major Depressive Disorder: A Randomized Controlled Trial
por: Chen, I-Peng, et al.
Publicado: (2022)

Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial
por: Gupta, Bhanu, et al.
Publicado: (2021)

Erratum: Correction of Acknowledgements Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update
por: Wang, Sheng-Min, et al.
Publicado: (2019)

Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression
por: Bruijnzeel, Dawn, et al.
Publicado: (2016)

Use of antipsychotics in the treatment of depressive disorders
por: Wang, Ping, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_171p8vjce766pt230r7he8qi9k